Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer Immunology Research|December 20, 2018
Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 AgonistFanny Polesso, Andrew D Weinberg, Amy E Moran
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2016
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In SituAmy E Moran, Fanny Polesso, Andrew D Weinberg
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2022
Restored Thymic Output after Androgen Blockade Participates in Antitumor ImmunityFanny Polesso, Breanna Caruso, Scott A Hammond, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2019
OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive FunctionFanny Polesso, Minhaz Sarker, Andrew D Weinberg, et al.
European Journal of Immunology|March 8, 2021
PD-1-specific "Blocking" antibodies that deplete PD-1<sup>+</sup> T cells present an inconvenient variable in preclinical immunotherapy experimentsFanny Polesso, Michael W Munks, Katherine H Rott, et al.
The Journal of Clinical Investigation|November 3, 2011
NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in miceSusan E Murray, Fanny Polesso, Alexander M Rowe, et al.
Neoplasia (New York, N.Y.)|April 9, 2008
The growth factor Midkine antagonizes VEGF signaling in vitro and in vivoEdward Htun van der Horst, Brendon T Frank, Lawrence Chinn, et al.
Nature|July 10, 2009
Chd1 regulates open chromatin and pluripotency of embryonic stem cellsAlexandre Gaspar-Maia, Adi Alajem, Fanny Polesso, et al.
Nature|March 24, 2022
Androgen receptor activity in T cells limits checkpoint blockade efficacyXiangnan Guan, Fanny Polesso, Chaojie Wang, et al.
Pageof 2